% | $
Quotes you view appear here for quick access.

ArQule Inc. Message Board

  • carylindsay1443 Jun 4, 2012 2:35 PM Flag

    Bad Time to Take the Kids to the 4th of July Party!

    ARQL got a bad draw of the cards by presenting on Saturday at ASCO. All the attendees where attending the fireworks at BMY, J&J, and ARQL was overlooked at the party, but finally today the good folks at Oppenheimer got around to putting a little wind at our back...

    Oppenheimer Discusses Compelling Data from ArQuel (ARQL) at ASCO

    8:16 am ET 06/04/2012 - Street Insider

    Oppenheimer commented on ArQule (NASDAQ: ARQL) following this weekend's ASCO noting compelling tivantinib ph.II 2nd-line HCC results.

    The firm comments, "The ph.II trial met the primary PFS endpoint, and tivantinib demonstrated significant TTP/PFS/OS benefit (HR=0.43/0.45/0.38) vs. placebo in the high c-MET expression subpopulation (~50% of pts), which, importantly, was a prespecified analysis. Notably, grade ¾ neutropenia was low (6%) at the 240mg, go-forward dose. Based on these results, we see a clear path to ph.III success, but ARQL currently reflects no value for this opportunity."

    The firm maintained their Outperform rating and price target of $11.00

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • J&J and Medivation are in prostate cancer. So, physicians treating CRC, HCC, RCC, and NSCLC did not go there.

      All these major investment houses con-ar tists (a.k.a analysts) are working for their paid clients. Their publicly-released analyses are pure stinking, lying, spinning POS.

      • 1 Reply to pharmainvestor11
      • Typical BS from spin-artists:

        "ArQule Inc. reported statistically significant increased overall survival in some liver cancer patients who were treated with its experimental drug tivantinib.

        ArQule faced criticism going into the ASCO meeting after releasing some data that showed a relatively small magnitude benefit when looking at time to progression and progression-free survival rates.

        The overall survival benefit, however, is "much more robust and clinically meaningful" in this set of data, said RBC Capital."

1.42-0.03(-2.07%)9:45 AMEDT